Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational studyAndrew Ip, Stuart L. Goldberg, Andrew L. Pecora et al.|PLoS ONE|2020Cited by 144
Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19Donald A. Berry, Stuart L. Goldberg, Andrew Ip et al.|PLoS ONE|2021Cited by 9